Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Mr Manuel J Antunes,
Tricuspid valve regurgitation (TR) occurs in approximately one third of patients with other cardiac valve disease, especially mitral disease. The co-existence of TR is a significant prognostic factor after surgery for left heart valve disease, if it is not corrected. Yet, only about 10% of patients have treatment for the tricuspid valve. Hence, a first appeal for the surgeons, as well as the cardiologists, to pay more attention to the tricuspid valve. Otherwise, late appearing TR will severely compromise survival. Organic tricuspid valve disease is rarer and is usually of rheumatic origin, although other pathologies may be associated. By contrast with mitral regurgitation, the diagnosis of the severity of TR is rather difficult. TR is associated with variable degrees of right ventricular (RV) dysfunction which is also particularly difficult to assess. This session included three talks on assessment of TR and RV function. Echocardiography remains the main tool but is not as accurate to identify the morphology of the tricuspid leaflets as with the mitral valve. 3-D echo has recently emerged as a better method for assessment of valve morphology and, although its definition still leaves a lot of room for improvement, it appears to be especially useful in the tricuspid valve. On the other hand, magnetic resonance (MR) is a useful tool to assess RV function. Although not as easily available as echocardiography, it is particularly suited for analysis of blood flows, which also permits a more accurate assessment of the regurgitant fraction. From the surgical point of view, it may also be helpful in indicating the special relationship of the RV to the sternum in the case of re-operation. Therefore, it remains a challenge to decide which patients require intervention on the tricuspid valve. Traditionally it was thought that by resolution of the left side valve pathology, “functional” TR would regress, but this does not always happen. Hence, it is current belief that moderate or severe TR should be addressed during surgery of the mitral (and/or aortic) valve. Late appearing TR, even in the presence of normal left side valves, should also be treated surgically before severe RV dysfunction ensues. Tricuspid valve replacement is very rarely required, except for severe organic disease. Annuloplasty techniques can successfully correct TR in the vast majority of cases. Annuloplasty can be performed either with rings or bands or by annular sutures, such as the Kay and the DeVega techniques. Some works suggest that rings achieve better long-term results but this is not consensual. My own experience with a modified DeVega technique demonstrated good and durable results.
Please do not forget the tricuspid valve in your assessment and management of left side valve pathology.
The tricuspid valve